Okra Polysaccharide Composition for Dietary Fat Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current obesity treatments, such as Orlistat and Sibutramine, come with significant side effects and cardiovascular risks, necessitating the development of new compositions to effectively manage weight and treat obesity and metabolic disorders without adverse effects.

Innovation Solution

A composition comprising edible parts of the okra plant species, a fructan, and a tricarboxylic acid, which reduces dietary fat absorption by binding with dietary fat in the stomach, thereby reducing calorie intake and alleviating obesity and metabolic diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing drugs like Orlistat are used to inhibit fat absorption, then fat absorption is reduced, but gastrointestinal side effects and liver damage occur

Engineering Contradiction:
Improvefat absorption reductionVSAvoidgastrointestinal side effects and liver damage
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses okra polysaccharides as an intermediary substance that binds to dietary fats in the gastrointestinal tract, forming a complex that prevents fat absorption. This natural polysaccharide mediator replaces harsh synthetic lipase inhibitors, achieving fat absorption reduction without the severe gastrointestinal and hepatic side effects associated with drugs like Orlistat

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs a natural, biodegradable polysaccharide from okra that acts as a temporary, disposable binding agent for dietary fats. This natural polymer is metabolized and excreted without accumulating in the body, avoiding long-term toxicity and organ damage while effectively reducing fat absorption during its functional period

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Reliability

If Sibutramine is used to suppress appetite, then body weight is reduced, but cardiovascular risks increase

Engineering Contradiction:
Improvebody weight reductionVSAvoidcardiovascular risks
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the pharmacological mechanism of Sibutramine (which affects neurotransmitter reuptake and appetite control) with a physical-chemical mechanism where okra polysaccharides bind to fats in the gastrointestinal tract. This substitution eliminates cardiovascular risks associated with central nervous system acting drugs while achieving weight reduction through direct fat binding and reduced caloric absorption

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If caloric intake is reduced through diet control, then weight loss is achieved, but lifestyle changes are difficult to implement

Engineering Contradiction:
Improveweight lossVSAvoidlifestyle change implementation
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The okra polysaccharide composition performs the fat-binding function automatically in the gastrointestinal tract without requiring active patient participation or behavior change. The polysaccharides self-bind to dietary fats upon ingestion, reducing caloric absorption passively while the patient maintains normal eating habits, thus achieving weight loss without difficult lifestyle modifications

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The okra-based composition effectively binds dietary fat, reducing absorption and promoting weight loss and management, while minimizing side effects, offering a safer alternative to existing treatments.

Implementation Method 1

The okra-based composition effectively binds dietary fat, reducing absorption

Methodology Applied
Scientific EffectAdsorption: Adsorption

Data Source

PatentEP3096767B1Composition comprising okra for use in reducing dietary fat absorption
Publication Date: 2018.06.06 OMEGA PHARMA INNOVATION & DEVELOPMENT NV
  • EP3096767B1 patent drawingFigure 1
  • EP3096767B1 patent drawingFigure 2
  • EP3096767B1 patent drawingFigure 3

AI summary

Composition comprising (optionally processed) edible parts of an okra plant species for use in reducing dietary fat absorption in a subject or for use in treating or preventing obesity and/or for use in treating or preventing a metabolic disease such as metabolic syndrome, or for managing the weight of a subject, by binding dietary fat in the subject's stomach.